Peripheral vasculopathy associated with methylphenidate treatment in children with Attention Deficit Hyperactivity Disorder
Downloads
Published
2014-12-17
How to Cite
Ordovás, M., Rodríguez Jiménez, E., Burgos, R., & Roldán, R. (2014). Peripheral vasculopathy associated with methylphenidate treatment in children with Attention Deficit Hyperactivity Disorder. Revista De Psiquiatría Infanto-Juvenil, 31(4), 36–42. Retrieved from https://aepnya.eu/index.php/revistaaepnya/article/view/134
Issue
Section
Case reports
Keywords:
methylphenidate, peripheral vascular disease, Raynaud’s SyndromeAbstract
We report the case of a girl who is diagnosed of Attention Deficit Hyperactivity Disorder who developed a secondary peripheral vascular disease (Raynaud’s Syndrome) after starting treatment with methylphenidate. The relationship between treatment with methylphenidate and the occurrence of peripheral vascular phenomena, its relevance and diagnostic and therapeutic implications are discussed.
Downloads
Download data is not yet available.
References
1. CIE-10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders- Text Revision, Fourth Edition. Washington, DC: American Psychiatric Association; 2000: 85-93.
2. Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998; 59 Suppl 7: 4–16.
3. Krull KR, Khan RB, Ness KK, Ledet D, Zhu L, Pui CH, Howard SC, Srivastava DK, Sabin ND, Hudson MM, Morris EB. Symptoms of attentiondeficit/hyperactivity disorder in long-term survivors of childhood leukemia. Pediatr Blood Cancer 2011; 57: 1191-6.
4. Uptodate. Bukstein O. Adult attention deficit hyperactivity disorder in adults: Epidemiology, pathogenesis, clinical features, course, assessment, and diagnosis [sede Web]. Aug 1, 2014. Uptodate.
5. Millichap JG. Etiologic classification of attentiondeficit/Hyperactivity disorders. Pediatrics 2008; 121: e358-65.
6. Cortese S. The neurobiology and genetics of Attention-Deficits/Hyperactivity Disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol 2012; 16: 422-33.
7. American Academy of Pediatrics, Subcommittee on Attention-Deficit/Hyperactivity Disorder, Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention deficit/hyperactivity disorder. Pediatrics 2001; 108: 1033–1044.
8. Grupo de trabajo de la Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en Niños y Adolescentes. Fundació Sant Joan de Déu, coordinador. Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en Niños y Adolescentes. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Agència d´Informació, Avaluació i Qualitat (AIAQS) de Cataluña; 2010. Guías de Práctica Clínica en el SNS: AATRM Nº
2007/18.
9. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. Great Britain: The British Psychological Society and The Royal College of Psychiatrist; 2009.
10. Bradley C. The Behavior of Children Receiving Benzedrine. Am J Psychiatry 1937; 94: 577–581.
11. Stahl SM. Psicofarmacología esencial de Stahl. Bases neurocientíficas y aplicaciones prácticas. Tercera edición. Madrid. Editorial Aula Médica. 2008.
12. Landsberg L, Young J. Fisiología y farmacología del sistema nervioso autónomo. En: Isselbacher K, Braunwald E, Wilson J D, Martin J, Fauci A, Kasper D, ed. Principios de medicina interna. 13ª ed. España: Interamericana-Mc Graw-Hill, 1994: vol 1: 481-497.
13. Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Funct 2005; 1 (1): 2.
14. Yu ZJ, Parker-Kotler C, Tran K, Weller RA, Weller EB. Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 2010; 12: 111-5.
15. Jefferson HJ, Jayne DR. Peripheral vasculopathy and nephropathy in association with phentermine. Nephrol Dial Transplant 1999; 14: 1761-3.
16. Pankl S, Pellegrini D, Bruetman JE. Chronic peripheral arterial disease induced by cocaine. Medicina Buenos Aires 2012; 72: 37-9.
17. Farmer RW, Malhotra PS, Mays MP, Egger ME, Smith JW, Jortani SA, Spiller H, Bosse GM, Callen JP, Franklin GA. Necrotizing peripheral vasculitis/vasculopathy following the use of cocaine laced with levamisole. J Burn Care Res 2012; 33: e6-e11.
18. Wolraich ML, McGuinn L, Doffing M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf 2007; 30: 17-26.
19. Goldman W, Seltzer R, Reuman P. Association between treatment with central nervous system stimulants and Raynaud’s syndrome in children: a retrospective case-control study of rheumatology patients. Arthritis Rheum 2008; 58: 563-6.
20. García-Carrasco M, Jiménez-Hernández M, Escárcega RO, Mendoza-Pinto C, Pardo-Santos R, Levy R, Maldonado CG, Chávez GP, Cervera R. Treatment of Raynaud’s phenomenon. Autoimmun Rev 2008; 8: 62-8.
21. Maricq HR, Carpentier PH, Weinrich MC, Keil JE, PaleschY, BiroC, et al. Geographic variation in the prevalence of Raynaud’s phenomenon: a region comparison. J Rheumatol 1997; 24: 879-89.
22. Tolosa C, Simeón CP, Gabarró L. El fenómeno de Raynaud. Med Clin 2009; 132: 712-8.
23. Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. J ClinRheumatol 2008; 14: 30-3.
2. Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998; 59 Suppl 7: 4–16.
3. Krull KR, Khan RB, Ness KK, Ledet D, Zhu L, Pui CH, Howard SC, Srivastava DK, Sabin ND, Hudson MM, Morris EB. Symptoms of attentiondeficit/hyperactivity disorder in long-term survivors of childhood leukemia. Pediatr Blood Cancer 2011; 57: 1191-6.
4. Uptodate. Bukstein O. Adult attention deficit hyperactivity disorder in adults: Epidemiology, pathogenesis, clinical features, course, assessment, and diagnosis [sede Web]. Aug 1, 2014. Uptodate.
5. Millichap JG. Etiologic classification of attentiondeficit/Hyperactivity disorders. Pediatrics 2008; 121: e358-65.
6. Cortese S. The neurobiology and genetics of Attention-Deficits/Hyperactivity Disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol 2012; 16: 422-33.
7. American Academy of Pediatrics, Subcommittee on Attention-Deficit/Hyperactivity Disorder, Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention deficit/hyperactivity disorder. Pediatrics 2001; 108: 1033–1044.
8. Grupo de trabajo de la Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en Niños y Adolescentes. Fundació Sant Joan de Déu, coordinador. Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en Niños y Adolescentes. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Agència d´Informació, Avaluació i Qualitat (AIAQS) de Cataluña; 2010. Guías de Práctica Clínica en el SNS: AATRM Nº
2007/18.
9. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. Great Britain: The British Psychological Society and The Royal College of Psychiatrist; 2009.
10. Bradley C. The Behavior of Children Receiving Benzedrine. Am J Psychiatry 1937; 94: 577–581.
11. Stahl SM. Psicofarmacología esencial de Stahl. Bases neurocientíficas y aplicaciones prácticas. Tercera edición. Madrid. Editorial Aula Médica. 2008.
12. Landsberg L, Young J. Fisiología y farmacología del sistema nervioso autónomo. En: Isselbacher K, Braunwald E, Wilson J D, Martin J, Fauci A, Kasper D, ed. Principios de medicina interna. 13ª ed. España: Interamericana-Mc Graw-Hill, 1994: vol 1: 481-497.
13. Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Funct 2005; 1 (1): 2.
14. Yu ZJ, Parker-Kotler C, Tran K, Weller RA, Weller EB. Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 2010; 12: 111-5.
15. Jefferson HJ, Jayne DR. Peripheral vasculopathy and nephropathy in association with phentermine. Nephrol Dial Transplant 1999; 14: 1761-3.
16. Pankl S, Pellegrini D, Bruetman JE. Chronic peripheral arterial disease induced by cocaine. Medicina Buenos Aires 2012; 72: 37-9.
17. Farmer RW, Malhotra PS, Mays MP, Egger ME, Smith JW, Jortani SA, Spiller H, Bosse GM, Callen JP, Franklin GA. Necrotizing peripheral vasculitis/vasculopathy following the use of cocaine laced with levamisole. J Burn Care Res 2012; 33: e6-e11.
18. Wolraich ML, McGuinn L, Doffing M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf 2007; 30: 17-26.
19. Goldman W, Seltzer R, Reuman P. Association between treatment with central nervous system stimulants and Raynaud’s syndrome in children: a retrospective case-control study of rheumatology patients. Arthritis Rheum 2008; 58: 563-6.
20. García-Carrasco M, Jiménez-Hernández M, Escárcega RO, Mendoza-Pinto C, Pardo-Santos R, Levy R, Maldonado CG, Chávez GP, Cervera R. Treatment of Raynaud’s phenomenon. Autoimmun Rev 2008; 8: 62-8.
21. Maricq HR, Carpentier PH, Weinrich MC, Keil JE, PaleschY, BiroC, et al. Geographic variation in the prevalence of Raynaud’s phenomenon: a region comparison. J Rheumatol 1997; 24: 879-89.
22. Tolosa C, Simeón CP, Gabarró L. El fenómeno de Raynaud. Med Clin 2009; 132: 712-8.
23. Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. J ClinRheumatol 2008; 14: 30-3.
© 2021 AEPNyA Todos los derechos reservados
